These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 25855495)

  • 1. Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection.
    He S; Lin B; Chu V; Hu Z; Hu X; Xiao J; Wang AQ; Schweitzer CJ; Li Q; Imamura M; Hiraga N; Southall N; Ferrer M; Zheng W; Chayama K; Marugan JJ; Liang TJ
    Sci Transl Med; 2015 Apr; 7(282):282ra49. PubMed ID: 25855495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, proof-of-concept clinical trial on repurposing chlorcyclizine for the treatment of chronic hepatitis C.
    Koh C; Dubey P; Han MAT; Walter PJ; Garraffo HM; Surana P; Southall NT; Borochov N; Uprichard SL; Cotler SJ; Etzion O; Heller T; Dahari H; Liang TJ
    Antiviral Res; 2019 Mar; 163():149-155. PubMed ID: 30711416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical Pharmacological Development of Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection.
    Rolt A; Le D; Hu Z; Wang AQ; Shah P; Singleton M; Hughes E; Dulcey AE; He S; Imamura M; Uchida T; Chayama K; Xu X; Marugan JJ; Liang TJ
    J Infect Dis; 2018 May; 217(11):1761-1769. PubMed ID: 29373739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chlorcyclizine Inhibits Viral Fusion of Hepatitis C Virus Entry by Directly Targeting HCV Envelope Glycoprotein 1.
    Hu Z; Rolt A; Hu X; Ma CD; Le DJ; Park SB; Houghton M; Southall N; Anderson DE; Talley DC; Lloyd JR; Marugan JC; Liang TJ
    Cell Chem Biol; 2020 Jul; 27(7):780-792.e5. PubMed ID: 32386595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pentagalloylglucose, a highly bioavailable polyphenolic compound present in Cortex moutan, efficiently blocks hepatitis C virus entry.
    Behrendt P; Perin P; Menzel N; Banda D; Pfaender S; Alves MP; Thiel V; Meuleman P; Colpitts CC; Schang LM; Vondran FWR; Anggakusuma ; Manns MP; Steinmann E; Pietschmann T
    Antiviral Res; 2017 Nov; 147():19-28. PubMed ID: 28923507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.
    Everson GT; Sims KD; Rodriguez-Torres M; Hézode C; Lawitz E; Bourlière M; Loustaud-Ratti V; Rustgi V; Schwartz H; Tatum H; Marcellin P; Pol S; Thuluvath PJ; Eley T; Wang X; Huang SP; McPhee F; Wind-Rotolo M; Chung E; Pasquinelli C; Grasela DM; Gardiner DF
    Gastroenterology; 2014 Feb; 146(2):420-9. PubMed ID: 24184132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retinoid derivative Tp80 exhibits anti-hepatitis C virus activity through restoration of GI-GPx expression.
    Nguyen BN; Okuno Y; Ajiro M; Iida K; Denawa M; Yamamoto M; Sakamoto N; Kagechika H; Hagiwara M
    J Med Virol; 2017 Jul; 89(7):1224-1234. PubMed ID: 27922182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ME3738 enhances the effect of interferon and inhibits hepatitis C virus replication both in vitro and in vivo.
    Abe H; Imamura M; Hiraga N; Tsuge M; Mitsui F; Kawaoka T; Takahashi S; Ochi H; Maekawa T; Hayes CN; Tateno C; Yoshizato K; Murakami S; Yamashita N; Matsuhira T; Asai K; Chayama K
    J Hepatol; 2011 Jul; 55(1):11-8. PubMed ID: 21145867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinically Approved Ion Channel Inhibitors Close Gates for Hepatitis C Virus and Open Doors for Drug Repurposing in Infectious Viral Diseases.
    Pietschmann T
    J Virol; 2017 Jan; 91(2):. PubMed ID: 27807238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-interferon-α neutralizing antibody induced telaprevir resistance under the interferon-α plus telaprevir treatment in vitro.
    Kuga C; Enomoto H; Aizawa N; Takashima T; Ikeda N; Ishii A; Sakai Y; Iwata Y; Tanaka H; Saito M; Iijma H; Nishiguchi S
    Biochem Biophys Res Commun; 2014 Nov; 454(3):453-8. PubMed ID: 25450683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France.
    Aherfi S; Solas C; Motte A; Moreau J; Borentain P; Mokhtari S; Botta-Fridlund D; Dhiver C; Portal I; Ruiz JM; Ravaux I; Bregigeon S; Poizot-Martin I; Stein A; Gérolami R; Brouqui P; Tamalet C; Colson P
    J Med Virol; 2014 Nov; 86(11):1868-76. PubMed ID: 25052594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitory effects of Pycnogenol® on hepatitis C virus replication.
    Ezzikouri S; Nishimura T; Kohara M; Benjelloun S; Kino Y; Inoue K; Matsumori A; Tsukiyama-Kohara K
    Antiviral Res; 2015 Jan; 113():93-102. PubMed ID: 25446333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New direct-acting antivirals' combination for the treatment of chronic hepatitis C.
    Asselah T; Marcellin P
    Liver Int; 2011 Jan; 31 Suppl 1():68-77. PubMed ID: 21205141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
    Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro infection of immortalized primary hepatocytes by HCV genotype 4a and inhibition of virus replication by cyclosporin.
    El-Farrash MA; Aly HH; Watashi K; Hijikata M; Egawa H; Shimotohno K
    Microbiol Immunol; 2007; 51(1):127-33. PubMed ID: 17237608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study.
    Manns M; Pol S; Jacobson IM; Marcellin P; Gordon SC; Peng CY; Chang TT; Everson GT; Heo J; Gerken G; Yoffe B; Towner WJ; Bourliere M; Metivier S; Chu CJ; Sievert W; Bronowicki JP; Thabut D; Lee YJ; Kao JH; McPhee F; Kopit J; Mendez P; Linaberry M; Hughes E; Noviello S;
    Lancet; 2014 Nov; 384(9954):1597-605. PubMed ID: 25078304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simeprevir and sofosbuvir for treatment of hepatitis C infection.
    Chopp S; Vanderwall R; Hult A; Klepser M
    Am J Health Syst Pharm; 2015 Sep; 72(17):1445-55. PubMed ID: 26294237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Novel Inhibitor IDPP Interferes with Entry and Egress of HCV by Targeting Glycoprotein E1 in a Genotype-Specific Manner.
    Lee M; Yang J; Jo E; Lee JY; Kim HY; Bartenschlager R; Shin EC; Bae YS; Windisch MP
    Sci Rep; 2017 Mar; 7():44676. PubMed ID: 28333153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Safety and efficacy of DCV-based DAAs therapy for chronic HCV infection in China].
    Wei JY; Lin DN; Wu ZB; Zhu JY; Zhao ZX; Mei YY; Lin CS; Zhang J; Zhang XH
    Zhonghua Gan Zang Bing Za Zhi; 2018 Dec; 26(12):933-939. PubMed ID: 30669787
    [No Abstract]   [Full Text] [Related]  

  • 20. Sofosbuvir and ribavirin in HCV genotypes 2 and 3.
    Zeuzem S; Dusheiko GM; Salupere R; Mangia A; Flisiak R; Hyland RH; Illeperuma A; Svarovskaia E; Brainard DM; Symonds WT; Subramanian GM; McHutchison JG; Weiland O; Reesink HW; Ferenci P; Hézode C; Esteban R;
    N Engl J Med; 2014 May; 370(21):1993-2001. PubMed ID: 24795201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.